scholarly journals Long non‐coding RNA s as an epigenetic regulator in human cancers

2017 ◽  
Vol 108 (10) ◽  
pp. 1927-1933 ◽  
Author(s):  
Yutaka Kondo ◽  
Keiko Shinjo ◽  
Keisuke Katsushima
2020 ◽  
Vol Volume 13 ◽  
pp. 6393-6403
Author(s):  
Wei Han ◽  
Jia Shi ◽  
Jiachao Cao ◽  
Bo Dong ◽  
Wei Guan

Author(s):  
Miaomiao Zhao ◽  
Songpo Wang ◽  
Qi Li ◽  
Qing Ji ◽  
Piaoting Guo ◽  
...  

2017 ◽  
Vol 50 (4) ◽  
pp. e12349 ◽  
Author(s):  
Yang Yu ◽  
Jian Yang ◽  
Quanpeng Li ◽  
Boming Xu ◽  
Yifan Lian ◽  
...  

Oncotarget ◽  
2017 ◽  
Vol 8 (55) ◽  
pp. 94997-95004 ◽  
Author(s):  
Yifan Zou ◽  
Jianfa Li ◽  
Yincong Chen ◽  
Huizhong Xiao ◽  
Fuyou Zhang ◽  
...  

2018 ◽  
Vol 7 (6) ◽  
pp. 1624-1633 ◽  
Author(s):  
Liang Shen ◽  
Changzhong Li ◽  
Ming Liu ◽  
Deying Wei ◽  
Qin Chang ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jie-yu Sun ◽  
Ming-ming Ni

AbstractThe last decade has witnessed the altered expression levels of long non-coding RNA HEIH in different types of cancer. More than half of the HEIH studies in cancer have been published within the last two years. To our knowledge, this is the first review to discuss very recent developments and insights into HEIH contribution to carcinogenesis. The functional role, molecular mechanism, and clinical significance of HEIH in human cancers are described in detail. The expression of HEIH is elevated in a broad spectrum of cancers, and its disorder contributes to cell proliferation, migration, invasion, and drug resistance of cancer cells through different underlying mechanisms. In addition, the high expression of HEIH is significantly associated with advanced tumor stage, tumor size and decreased overall survival, suggesting HEIH may function as a prognostic biomarker and potential therapeutic target for human cancers.


Oncotarget ◽  
2017 ◽  
Vol 8 (37) ◽  
pp. 62454-62462 ◽  
Author(s):  
Peng-Ju Ma ◽  
Qing-Kai Guan ◽  
Lei Meng ◽  
Nan Qin ◽  
Jia Zhao ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document